• Je něco špatně v tomto záznamu ?

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides

L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, L. Maletínská

. 2020 ; 11 (-) : 597583. [pub] 20201126

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019793

Obesity, diabetes, insulin resistance, sedentary lifestyle, and Western diet are the key factors underlying non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases in developed countries. In many cases, NAFLD further progresses to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and to hepatocellular carcinoma. The hepatic lipotoxicity and non-liver factors, such as adipose tissue inflammation and gastrointestinal imbalances were linked to evolution of NAFLD. Nowadays, the degree of adipose tissue inflammation was shown to directly correlate with the severity of NAFLD. Consumption of higher caloric intake is increasingly emerging as a fuel of metabolic inflammation not only in obesity-related disorders but also NAFLD. However, multiple causes of NAFLD are the reason why the mechanisms of NAFLD progression to NASH are still not well understood. In this review, we explore the role of food intake regulating peptides in NAFLD and NASH mouse models. Leptin, an anorexigenic peptide, is involved in hepatic metabolism, and has an effect on NAFLD experimental models. Glucagon-like peptide-1 (GLP-1), another anorexigenic peptide, and GLP-1 receptor agonists (GLP-1R), represent potential therapeutic agents to prevent NAFLD progression to NASH. On the other hand, the deletion of ghrelin, an orexigenic peptide, prevents age-associated hepatic steatosis in mice. Because of the increasing incidence of NAFLD and NASH worldwide, the selection of appropriate animal models is important to clarify aspects of pathogenesis and progression in this field.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019793
003      
CZ-PrNML
005      
20210830101404.0
007      
ta
008      
210728s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fendo.2020.597583 $2 doi
035    __
$a (PubMed)33324348
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kořínková, L $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czechia
245    10
$a Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides / $c L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, L. Maletínská
520    9_
$a Obesity, diabetes, insulin resistance, sedentary lifestyle, and Western diet are the key factors underlying non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases in developed countries. In many cases, NAFLD further progresses to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and to hepatocellular carcinoma. The hepatic lipotoxicity and non-liver factors, such as adipose tissue inflammation and gastrointestinal imbalances were linked to evolution of NAFLD. Nowadays, the degree of adipose tissue inflammation was shown to directly correlate with the severity of NAFLD. Consumption of higher caloric intake is increasingly emerging as a fuel of metabolic inflammation not only in obesity-related disorders but also NAFLD. However, multiple causes of NAFLD are the reason why the mechanisms of NAFLD progression to NASH are still not well understood. In this review, we explore the role of food intake regulating peptides in NAFLD and NASH mouse models. Leptin, an anorexigenic peptide, is involved in hepatic metabolism, and has an effect on NAFLD experimental models. Glucagon-like peptide-1 (GLP-1), another anorexigenic peptide, and GLP-1 receptor agonists (GLP-1R), represent potential therapeutic agents to prevent NAFLD progression to NASH. On the other hand, the deletion of ghrelin, an orexigenic peptide, prevents age-associated hepatic steatosis in mice. Because of the increasing incidence of NAFLD and NASH worldwide, the selection of appropriate animal models is important to clarify aspects of pathogenesis and progression in this field.
650    _2
$a zvířata $7 D000818
650    _2
$a regulace chuti k jídlu $x účinky léků $7 D001069
650    12
$a modely nemocí na zvířatech $7 D004195
650    _2
$a progrese nemoci $7 D018450
650    12
$a přijímání potravy $7 D004435
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x farmakologie $7 D007004
650    _2
$a zánět $x komplikace $7 D007249
650    _2
$a nealkoholová steatóza jater $x farmakoterapie $x etiologie $x patofyziologie $7 D065626
650    _2
$a peptidové fragmenty $x farmakologie $7 D010446
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Pražienková, V $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czechia
700    1_
$a Černá, L $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czechia
700    1_
$a Karnošová, A $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czechia
700    1_
$a Železná, B $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czechia
700    1_
$a Kuneš, J $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czechia $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
700    1_
$a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czechia
773    0_
$w MED00174543 $t Frontiers in endocrinology $x 1664-2392 $g Roč. 11, č. - (2020), s. 597583
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33324348 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101405 $b ABA008
999    __
$a ok $b bmc $g 1690577 $s 1140239
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c - $d 597583 $e 20201126 $i 1664-2392 $m Frontiers in endocrinology $n Front. endocrinol. $x MED00174543
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...